



Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number			
(Use several sheets if necessary)				Filing Date			
				First Name Inventor			
				Group Art Unit			
				Examiner Name			
Sheet 1 of 3				Attorney Docket Number			
U.S. PATENT DOCUMENTS							
Examiner Initials'	Cite No.'	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ¹ (if known)				
<i>ms</i>	A1	5,856,529		Bristol-Myers Squibb Company	01/05/1999		
	A2	6,121,397		Xerox Corporation	09/19/2000		
	A3	5,089,514		Bernard Hulin	02/18/1992		
	A4	4,011,326		Jensen	03/08/1977		
	A5	6,291,685		Junghans, et. al.	09/18/2001		
	A6	6,441,185		Kühnle, et. al.	08/27/2002		
	A7	5,599,826		Mertens, et. al.	02/04/1997		
	A8	4,598,089		Hadvary, et. al.	07/01/1986		
✓	A9	6,004,996		Shah, et. al.	12/21/1999		
FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No.'	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
<i>ms</i>	B1	EP 1 078 923			F. Hoffmann-La Roche A.G.	02/28/2001	
	B2	EP 0903343			SSP Co., Ltd.	03/24/1999	
	B3	EP 185,359			F. Hoffmann-La Roche A.G.	06/25/1986	
	B4	EP 189,577			F. Hoffmann-La Roche A.G.	08/06/1986	
	B5	EP 443,449			F. Hoffmann-La Roche A.G.	08/28/1991	
	B6	EP 524,495			F. Hoffmann-La Roche & Co.	01/27/1993	
	B7	WO 99/10339			Pfizer Products Inc.	03/04/1999	
	B8	WO 02 16331			Eli Lilly & Company	02/28/2002	
	B9	WO 00 08002			Glaxo Group Limited	02/17/2000	X
	B10	WO 91/19702			Pfizer Inc.	12/26/1991	
	B11	WO 94/01420			Smithkline Beecham PLC.	01/20/1994	
	B12	WO 94/13650			Smithkline Beecham PLC.	06/23/1994	
	B13	WO 95/17394			Smithkline Beecham PLC	06/29/1995	
	B14	WO 97/25042			Smithkline Beecham PLC	07/17/1997	
✓	B15	WO 99/08501			Dr. Reddy's Research Foundation	02/25/1999	


ms

2/17/06

<i>m</i>	B16	WO 00/09122	F. Hoffmann-La Roche AG	02/24/2000	
<i>/</i>	B17	WO 00/09123	F. Hoffmann-La Roche AG	02/24/2000	
<i>/</i>	B18	WO 0100603	Glaxo Group Limited	01/04/2001	
<i>/</i>	B19	WO 03/053976	Biovit-rum AB	07/03/2003	
<i>✓</i>	B20	WO 03/004458	Biovit-rum AB	01/16/2003	
Examiner Signature <i>m</i>	Date Considered <i>D. Gumbler</i>			<i>2/7/06</i>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Application Number	10/719,556
		Filing Date	November 21, 2003
		First Name Inventor	Binggeli
		Group Art Unit	
		Examiner Name	
Sheet 3	Of 3	Attorney Docket Number	21461 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>mm</i>	C1	Keller and Wahli: Trends Endocrin. Metab. (1993); 4:291-296	
	C2	MacDougald and Lane: Current Biology Vol. 5 pp. 618-621 (1995)	
	C3	Guerre-Millo, et. al.; J Biol Chem 2000; 275: 16638-16642	
	C4	Balfour, et. al.; Drugs 57 (1999) 921-930	
	C5	Haigh et. al., Tetrahedron: Asymmetry, 10, pp. 1353-1367	
	C6	Gotteland et al., Synlett, 9 pp. 931-932 (1995)	
	C7	Hulin et al., J. Med. Chem., 39, pp. 3897-3907 (1996)	
	C8	Nicolaou et al., J. Am. Chem. Soc., 122, pp. 3830-3838 (2000)	
	C9	Nichols et al., Anal. Biochem., 257, pp. 112-119 (1998)	
	C10	Einsiedel et. al., Bioorg. Med. Chem. Lett., 10, pp. 2041-2044 (2000)	
	C11	Goto et al., Chem. Pharm. Bull., 19, pp. 2050-2057 (1971)	
	C12	Reichstein et al., Helvetica Chimica Acta, 16, pp. 121-129 (1933)	
	C13	Diels et al., chem.. Ber., 48, pp. 897-905 (1915)	
	C14	Wightman et al., J. Org. chem., 43, pp. 2167-2170 (1978)	
	C15	Musser et al., J. Med. Chem. 30, pp. 62-67 (1987)	
	C16	Rahman et al., J. Chem. Soc. Perkin Trans. 1, 12, pp. 2973-2977 (1983)	
	C17	Kelly et. al., J. Am. Chem. Soc., 110, pp. 6471-6480 (1988)	
	C18	Kneen et al., Synthetic Communications, 16, pp. 1635-1640 (1986)	
	C19	Kim et al., Can. J. Chem., 60, pp. 2093-2098 (1982)	
	C20	Pàrkányi et al., Monatsh. Chem., 123, pp. 637-645 (1992)	
	C21	STN International @ CAPLUS Database, Accession No. 2000; 117035; Collins et al., WO 2000008002, abstract	
	C22	Malamas, MS et al, Eur. J. Med. Chem. Vol. 36, No. 1 (2001) pp. 31-42	
	C23	Hulin, B. et al., Current Pharmaceutical Design, Vol.2 (1996) pp. 85-102	
	C24	Oplinger, et. al., ACS National Meeting, San Diego, April 1-5, 2001, Poster 238, Division of Medicinal Chemistry, Section C	
<i>✓</i>	C25	Gustavsson, et. al., Chemical Abstracts, Vol. 138, No. 106,504 (2003)	
Examiner Signature	<i>D. Lamberson</i>		DATE CONSIDERED <i>2/7/06</i>

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³Applicant is to place a check mark here if English language Translation or abstract is attached.

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

form with neat communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

form with next communication to applicant.
¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Alfred Binggeli et al

Group: 1632

Serial No. 10/719,556, filed November 21, 2003
(Reference No. 21461 US)

Examiner:

For: INDOLYL DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110

Date: September 1, 2004

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the enclosed PCT Written Opinion.

Enclosed is a PCT Written Opinion, dated June 11, 2004, which was issued by the European Patent Office in PCT/EP 03/12814 application corresponding to the captioned application. The PCT Written Opinion lists Document B21 (EP 0 780 389), Document B22 (WO 02/092084), C26 (RAMI H. K. et al, *Synthetic ligands for PPAR gamma-review of patent literature 1994-1999*, Expert Opinion on Therapeutic Patents, Vol. 10, No. 5, pgs. 623-634 (2000), and C27 (HENKE B.R. et al, *Synthesis and Biological Activity of a Novel Series of Indole-Derived PPARgamma Agonists*, Bioorganic & Medicinal Chemistry Letters, Vol. 9, No. 23, pgs. 3329-3334 (1999). Documents B21, B22, C26 and C27 are not being submitted because they have been made of record in a Supplemental Information Disclosure Statement sent to the USPTO on June 22, 2004.